GlassScriptPhysician profile
Nisida Berberi
NPI 1942596630
$3,008.41
in general payments reported to CMS, 2019-2025
21 companies · $841 in 2025
The $841 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.89 · 2021: $23.84 · 2022: $628 · 2023: $1,408 · 2024: $21.03 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,462 · Consulting Fee: $800 · Education: $7.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,461.99 |
| Consulting Fee | $800.00 |
| Education | $7.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,324.50 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Ucb, INC. | $623.64 | 2022-2023 | Fintepla, Briviact |
| Immedica Pharma US, INC. | $211.25 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $126.17 | 2023 | Aptiom |
| Neurelis, INC. | $113.96 | 2022-2025 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $104.33 | 2022-2023 | Rexulti |
| Impel Pharmaceuticals INC. | $93.32 | 2022-2023 | Trudhesa |
| Aquestive Therapeutics, INC. | $72.58 | 2019-2022 | |
| Lilly USA, LLC | $47.49 | 2023 | Reyvow, Emgality |
| Jazz Pharmaceuticals INC. | $41.97 | 2023 | Epidiolex |
| Genzyme Corporation | $40.74 | 2019 | |
| Ironshore Pharmaceuticals INC. | $37.33 | 2022-2023 | Jornay Pm |
| Abbvie INC. | $26.87 | 2025 | |
| Abbott Laboratories | $23.84 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $23.42 | 2023 | Austedo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $21.03 | 2024 | Shingrix |
| Biocodex, INC. | $19.49 | 2023 | Diacomit |
| Catalyst Pharmaceuticals, INC. | $17.39 | 2023 | Fycompa |
| Neos Therapeutics, LP | $17.36 | 2023 | Adzenys Xr-Odt |
| Novo Nordisk INC | $13.91 | 2019 | |
| Travere Therapeutics, INC. | $7.82 | 2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisida Berberi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.